Skip to content

Advanced Glycation Endproducts (AGEs) and their impact on transport proteins, inflammation and body composition of hemodialysis patients compared to healthy subjects

Advanced Glycation Endproducts (AGEs) and their impact on transport proteins, inflammation and body composition of hemodialysis patients compared to healthy subjects - AGEs and transport proteins

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00033331
Enrollment
30
Registered
2024-03-01
Start date
2024-03-11
Completion date
Unknown
Last updated
2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

healthy subjects for comparison N18.5

Interventions

Group 1: A single blood sample (41.1 ml) and a bioelectrical impedance measurement (using NutriGard MS, DATA Input) will be carried out in 10 healthy volunteers (group A, people of younger age, see in

Sponsors

Martin-Luther-Universität Halle-Wittenberg, Universitätsmedizin Halle, Klinik für Innere Medizin II
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: a) healthy subjects (Group A, young people) - Age: > 18 to 30 years inclusive - written informed consent b) healthy subjects (Group B, moderate old people) - Age: > 40 to 70 years inclusive - written informed consent c) moderate old hemodialysis patients (Group C) - Age: > 40 to 70 years inclusive - written informed consent - endstage renal disease, hemodialysis therapy for at least 3 months

Exclusion criteria

Exclusion criteria: a) healthy subjects (Group A, young people) - known malignant tumor disease - impaired kidney function (eGFR 50mg/l, fever, chills) - Diabetes mellitus (HbA1c 50mg/l, fever, chills) - Diabetes mellitus (HbA1c 50mg/l, fever, chills) - Diabetes mellitus (HbA1c < 40 mmol/mol IFCC) - psychiatric or neurological illnesses that impair the ability to consent - known pregnancy or lack of contraception (premenopausal women)

Design outcomes

Primary

MeasureTime frame
The primary endpoint is to examine the difference in AGE-contaminated transport proteins between hemodialysis patients and an age-matched group of healthy volunteers. The evaluation is carried out using descriptive statistics and correlation respectively.

Secondary

MeasureTime frame
The following are taken into account as secondary endpoints: - difference in AGE-contaminated transport proteins in the healthy control group compared to a younger control group - correlation of AGE concentrations with parameters of the inflammatory/anti-inflammatory axis (IL-6, IL-10) - influence of AGE exposure on the regulation of the inflammatory cascade (measurement of microRNAs: miR-142-3p and miR-142-5p) - differences in bioelectrically determined nutritional parameters between the examined groups - correlation of bioelectrical impedance analysis with the AGE load of the transport proteins and the inflammatory markers.

Countries

Germany

Contacts

Public ContactRoman Fiedler

Martin-Luther-Universität Halle-Wittenberg, Universitätsmedizin Halle, Klinik für Innere Medizin II

roman.fiedler@uk-halle.de+49 345 5572717

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026